Assessment of high-efficacy agonism in synthetic cannabinoid receptor agonists containing l-tert-leucinate
Christopher Lucaj, Charlotte Pitha, Jordan Davis, Hideaki Yano, bioRxiv 2024.10.11.617959; doi: https://doi.org/10.1101/2024.10.11.617959
Characterization of Gαs and Gαolf activation by catechol and non-catechol dopamine D1 receptor agonists.
Nguyen AM, Semeano A, Quach V, Inoue A, Nichols DE, Yano H, Characterization of Gαs and Gαolf activation by catechol and non-catechol dopamine D1 receptor agonists. bioRxiv preprint. 2024 Jan. 7; https://doi.org/10.1101/2023.10.03.560682.
Linkers in Bitopic Agonists Shape Bias Profile among Transducers for the Dopamine D2 and D3 Receptors
Semeano A, Garland R, Bonifazi A, Lee KH, Famiglietti J, Zhang W, Jo YJ, Battiti FO, Shi L, Newman AH, Yano H. Linkers in Bitopic Agonists Shape Bias Profile among Transducers for the Dopamine D2 and D3 Receptors. ACS Pharmacol Transl Sci. 2024 Aug 9;7(8):2333-2349. doi: 10.1021/acsptsci.4c00119. eCollection 2024 Aug 9. PubMed PMID: 39144557; PubMed Central PMCID: PMC11320723.
Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
Yano H, Chitsazi R, Lucaj C, Tran P, Hoffman AF, Baumann MH, Lupica CR, Shi L. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor. ACS Chem Neurosci. 2023 Nov 1;14(21):3928-3940. doi: 10.1021/acschemneuro.3c00530. Epub 2023 Oct 17. PubMed PMID: 37847546; PubMed Central PMCID: PMC10623572.
Fine-tuning GPCR-mediated neuromodulation by biasing signaling through different G protein subunits.
Park JC, Luebbers A, Dao M, Semeano A, Nguyen AM, Papakonstantinou MP, Broselid S, Yano H, Martemyanov KA, Garcia-Marcos M. Fine-tuning GPCR-mediated neuromodulation by biasing signaling through different G protein subunits. Mol Cell. 2023 Jul 20;83(14):2540-2558.e12. doi: 10.1016/j.molcel.2023.06.006. Epub 2023 Jun 29. PubMed PMID: 37390816; PubMed Central PMCID: PMC10527995.
Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma.
Pavletić P, Semeano A, Yano H, Bonifazi A, Giorgioni G, Piergentili A, Quaglia W, Sabbieti MG, Agas D, Santoni G, Pallini R, Ricci-Vitiani L, Sabato E, Vistoli G, Del Bello F. Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma. J Med Chem. 2022 Sep 22;65(18):12124-12139. doi: 10.1021/acs.jmedchem.2c00840. Epub 2022 Sep 13. PubMed PMID: 36098685; PubMed Central PMCID: PMC9511495.